Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Randomized, Double-blind, Placebo-controlled, First-in-human Phase 1 Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine "fH1/DSP-0546LP" After Intramuscular (IM) Administrations in Healthy Adults

Next Previous
X
Search
Trial Profile

A Single Center, Randomized, Double-blind, Placebo-controlled, First-in-human Phase 1 Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine "fH1/DSP-0546LP" After Intramuscular (IM) Administrations in Healthy Adults

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FH1 DSP 0546LP (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Sumitomo Pharma

    • Most Recent Events

    • 15 Jul 2024 Status changed from not yet recruiting to recruiting.
    • 19 Jun 2024 New trial record
    • 14 May 2024 According to Sumitomo Pharma media release, Sumitomo Pharma and NIBIOHN announced today that they have commenced a Phase 1 clinical study on fH1/DSP-0546LP a universal influenza vaccine candidate formulation, in Europe.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top